SC-SENSOR-ELECTRONIC
Sensor Electronic Technology, Inc. (“SETi”), a leading global innovator of deep UV LED products and technology, announced that it successfully obtained a permanent injunction in a patent infringement lawsuit against Bolb, Inc. (“Bolb”), and Quantum Egg, Inc. (“Q-Egg”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005031/en/
The California Northern District federal court issued a permanent injunction against the sales of an accused UV LED sterilizer device, as well as any mere colorable variations, according to the parties’ stipulation. The Court will therefore prohibit the sale of similar products if they prove to be mere colorable variations of the accused products.
The asserted patents in this litigation cover fundamental UV LED technology, encompassing UV LED sterilizer structures and drivers, chip fabrication, and epitaxial layer growth.
Bolb is a UV LED company co-founded by former SETi employees, and Q-Egg was the distributor of the accused UV LED sterilizer device.
The UV LED market has expanded to a range of fields, including air and water purification devices, as well as medical and bio devices for skin care. The UV LED market value will grow up to $1.2 billion in 2022 according to a market report from LEDinside (2018).
SETi has also collaborated with South Korean UV LED company Seoul Viosys Co., Ltd. (“SVC”), resulting in the development of Violeds technology for UV LED-based disinfection, deodorization, phototherapy and curing. Violeds technology has been used by the US National Aeronautics and Space Administration (NASA) aboard the International Space Station (ISS). SETi also supplies UV LED products to America’s largest heating and cooling manufacturing brand company. This product has been recognized by customers for its high performance in sterilizing various bacteria that live inside air conditioner equipment and preventing it from spreading inside a home or office during operation.
“It is difficult to survive on a long-term basis in the UV LED industry without a strong foundation in intellectual property and technology expertise, something that SETi and SVC have gained thanks to their extensive investment in research and development,” said Chae Hon Kim, CEO of SETi.
“SETi believes in furthering a market of fair competition and investment in intellectual property. We believe that this rewards research and development, allowing entrepreneurs and small businesses to have their hard work recognized in the marketplace. We also believe in the importance of green technology. As a UV LED pioneer developing commercialized UV LED for the first time in the word, we plan to make our products available at even more competitive pricing to encourage the distribution of our green technology products in the market, thereby contributing to a clean and healthy environment,” added Kim.
Semicon Light Co, Ltd., an investor of Bolb, did sales promotion for the accused UV LED and sterilizer device UV LEDs in Japan and other countries.
About SETi
Sensor Electronic Technology, inc. (SETi), a division of Seoul Semiconductor (KOSDAQ 046890) and Seoul Viosys, is the world’s leading supplier of deep UV LEDs (emission wavelengths shorter than 340nm), as well as a broad portfolio of UV-B, and UV-C LED products and application solutions. SETi UV LEDs are certified to AS9100D with ISO 9001:2015, and the company is committed to meeting and exceeding the needs of customers and stakeholders through the highest level of quality management. To learn more, visit http://www.s-et.com/en/ .
About Seoul Viosys
Seoul Viosys is the world’s first UV LED solution provider. Established in 2002 as a subsidiary of Seoul Semiconductor, the company developed EPI, FAB, and UV LEDs. In 2005, it produced UVC LEDs of 275nm, 310nm and 340nm for the first time in the world. In 2007, it achieved mass production of Deep UV LEDs for 255nm~340nm and has become the only company to produce UV LEDs of all wavelengths. Seoul Viosys has more than 6,000 patents related to UV LED technology. Its UV LED modules provide strong sterilization and disinfection (UVC), skin regeneration (UVB) and effective cultivation for horticulture. It is an eco-friendly and healthy product with no harmful chemicals unlike conventional mercury lamps. The key products have been applied to applications for water/air purification and sterilization are opening new application possibilities for horticulture, residential, commercial, water treatment facilities, health care, and even automobiles. To learn more, visit http://www.seoulviosys.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191205005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Original “Titanic Cherub” From James Cameron’s Epic Film Heads to Auction December 9 & 1024.11.2025 21:48:00 CET | Press release
Iconic Hollywood Artifact Indelibly Linked with “Jack & Rose” Portrayed by Kate Winslet and Leonardo DiCaprio One of the most recognizable and beloved set pieces from James Cameron’s Titanic heads to auction on December 9 &10 —the original Grand Staircase Cherub, seen in multiple scenes of the 1997 blockbuster, including the pivotal moment when Jack and Rose meet in front of the First Class Dining Room and the climactic moment when the Atlantic Ocean bursts through the skylight and floods the staircase, and cherub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124056883/en/ The iconic “cherub” with Leonardo DiCaprio & Kate Winslet in James Cameron’s “TITANIC”. The ornate fixture—crafted for the full-scale recreation of Titanic’s Grand Staircase—was gifted by the production to Martin Biallas, CEO of SEE Global Entertainment, whose immersive exhibitions have brought the world’s most famous ship to millions of fans. It now
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 16:10:00 CET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 15:05:00 CET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 14:17:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
